NASDAQ:ADILAdial Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Adial Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.57 -0.01 (-0.50 %) (As of 06/4/2020 04:00 PM ET) Add Compare Share Today's Range$1.55Now: $1.57▼$1.6450-Day Range$1.30MA: $1.46▼$1.7052-Week Range$1.00Now: $1.57▼$3.17Volume6,200 shsAverage Volume65,729 shsMarket Capitalization$16.71 millionP/E RatioN/ADividend YieldN/ABeta0.93 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAdial Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Adial Pharmaceuticals has a potential upside of 218.0% from its current price of $1.57.Amount of Analyst CoverageAdial Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.0 Community Rank Outperform VotesAdial Pharmaceuticals has received 93 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAdial Pharmaceuticals has received 140 “underperform” votes. (Add your “underperform” vote.)Community SentimentAdial Pharmaceuticals has received 60.09% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Adial Pharmaceuticals and other stocks. Vote “Outperform” if you believe ADIL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ADIL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAdial Pharmaceuticals does not currently pay a dividend.Dividend GrowthAdial Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adial Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $39,098.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders40.81% of the stock of Adial Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 6.00% of the stock of Adial Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioAdial Pharmaceuticals has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.90 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADIL Previous Symbol CUSIPN/A CIK1513525 Webwww.adialpharma.com Phone434-422-9800Debt Debt-to-Equity RatioN/A Current Ratio15.22 Quick Ratio15.22Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book2.28Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-8,590,000.00 Net MarginsN/A Return on Equity-103.99% Return on Assets-96.82%Miscellaneous Employees3 Outstanding Shares10,630,000Market Cap$16.71 million Next Earnings Date8/11/2020 (Estimated) OptionableNot Optionable NASDAQ:ADIL Rates by TradingView Receive ADIL News and Ratings via Email Sign-up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter. Adial Pharmaceuticals (NASDAQ:ADIL) Frequently Asked Questions How has Adial Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Adial Pharmaceuticals' stock was trading at $1.35 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ADIL stock has increased by 16.5% and is now trading at $1.5721. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Adial Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adial Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Adial Pharmaceuticals. When is Adial Pharmaceuticals' next earnings date? Adial Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Adial Pharmaceuticals. How were Adial Pharmaceuticals' earnings last quarter? Adial Pharmaceuticals Inc (NASDAQ:ADIL) announced its quarterly earnings data on Thursday, May, 14th. The company reported ($0.22) earnings per share (EPS) for the quarter. View Adial Pharmaceuticals' earnings history. What price target have analysts set for ADIL? 1 equities research analysts have issued 1-year price targets for Adial Pharmaceuticals' shares. Their forecasts range from $5.00 to $5.00. On average, they expect Adial Pharmaceuticals' share price to reach $5.00 in the next year. This suggests a possible upside of 218.0% from the stock's current price. View analysts' price targets for Adial Pharmaceuticals. Has Adial Pharmaceuticals been receiving favorable news coverage? Press coverage about ADIL stock has been trending negative on Friday, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Adial Pharmaceuticals earned a news sentiment score of -2.7 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutAdial Pharmaceuticals. Are investors shorting Adial Pharmaceuticals? Adial Pharmaceuticals saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 4,500 shares, a drop of 45.8% from the April 30th total of 8,300 shares. Based on an average daily volume of 94,000 shares, the short-interest ratio is presently 0.0 days. Approximately 0.1% of the shares of the stock are sold short. View Adial Pharmaceuticals' Current Options Chain. Who are some of Adial Pharmaceuticals' key competitors? Some companies that are related to Adial Pharmaceuticals include Capricor Therapeutics (CAPR), Trevi Therapeutics (TRVI), VERONA PHARMA P/S (VRNA), Aridis Pharmaceuticals (ARDS), Vaccinex (VCNX), Aclaris Therapeutics (ACRS), ASLAN PHARMACEU/ADR (ASLN), American Brivision (Holding) (ABVC), Evoke Pharma (EVOK), Zosano Pharma (ZSAN), Diffusion Pharmaceuticals (DFFN), OncoSec Medical (ONCS), Eyenovia (EYEN), Vascular Biogenics (VBLT) and Infinity Pharmaceuticals (INFI). View all competitors. What other stocks do shareholders of Adial Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adial Pharmaceuticals investors own include Global Partners (GLP), Corbus Pharmaceuticals (CRBP), Adobe (ADBE), Tandem Diabetes Care (TNDM), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Altria Group (MO) and Vertex Pharmaceuticals (VRTX). Who are Adial Pharmaceuticals' key executives? Adial Pharmaceuticals' management team includes the following people: Mr. William B. Stilley III, M.B.A., MBA, CEO, Pres, Sec., Treasurer & Director (Age 51)Prof. Bankole A. Johnson DSc, Ph.D., M.D., M.Phil, FRCPsych, Founder & Chief Medical Officer (Age 59)Mr. Joseph M. Truluck M.B.A., MBA, CFO & COO (Age 41)Ms. Monika Z. Rogozinska, Chief Devel. OfficerMr. Alex Lugovoy, Head of Strategy When did Adial Pharmaceuticals IPO? (ADIL) raised $8 million in an initial public offering (IPO) on Friday, July 27th 2018. The company issued 1,500,000 shares at $5.00 per share. Joseph Gunnar & Co. acted as the underwriter for the IPO and Dawson James Securities was co-manager. What is Adial Pharmaceuticals' stock symbol? Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL." How do I buy shares of Adial Pharmaceuticals? Shares of ADIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Adial Pharmaceuticals' stock price today? One share of ADIL stock can currently be purchased for approximately $1.57. How big of a company is Adial Pharmaceuticals? Adial Pharmaceuticals has a market capitalization of $16.71 million. Adial Pharmaceuticals employs 3 workers across the globe. What is Adial Pharmaceuticals' official website? The official website for Adial Pharmaceuticals is www.adialpharma.com. How can I contact Adial Pharmaceuticals? Adial Pharmaceuticals' mailing address is 1180 Seminole Trail Suite 495, Charlottesville VA, 22901. The company can be reached via phone at 434-422-9800 or via email at [email protected] This page was last updated on 6/5/2020 by MarketBeat.com Staff
